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Since the early 20th century, many countries 
have been experiencing an epidemiological transition, 
characterized by an increase not only in the population 
life expectancy, but also in the prevalence of chronic 
and degenerative diseases.1 In this context, the study of 
pathophysiological mechanisms behind the aging process 
has become a relevant field of research as it may provide 
scientific basis to the development of new resources of 
diagnosis and treatment. One of the main theories proposed 
to explain the aging phenomenon is the Mitochondrial 
Free Radical Theory of Aging. According to this theory, 
reactive oxygen species (ROS) generated in oxidative 
phosphorylation damage mitochondrial macromolecules, 
leading to mitochondrial dysfunction and signaling for 
cellular senescence.2 ROS are also known to stimulate the 
mitochondriogenesis (generation of new mitochondria) 
through a molecular pathway that involves the peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) and the mitochondrial transcription factors A, 
B1 and B2 (TFAM, TFB1M and TFB2M).3 Given that 
ROS take part in both aging and mitochondriogenesis, 
the Laboratory of Molecular and Cellular Biology of the 
University of Sao Paulo Faculty of Medicine investigated 
the relationship between age, mitochondria amount and 
the expressions of PGC-1α, TFAM, TFB1M and TFB2M 
in brain tissue.
For this investigation, 60 human brain samples 
were collected during autopsy procedures in the Death 
Verification Service of the Capital (SVOC), as well as the 
clinical history of each donor. The samples were transported 
to the Laboratory and their DNA and RNA were extracted. 
The mitochondria amount of the samples was accessed 
by the measurement of the ratio between the quantity of a 
mitochondrial encoded gene and a nuclear encoded gene, 
using quantitative polymerase chain reaction (qPCR). 
The expressions of PGC-1α, TFAM, TFB1M and TFB2M 
were also determined through qPCR and the raw data was 
submitted to statistical analysis.
It was found that specimens with more than 1000 
copies of mtDNA had a direct correlation between mtDNA 
content and age, while those with less than 1000 copies, 
did not present any correlation (Figure 1). These results 
suggest that mtDNA content does not vary in the same 
way during aging among individuals, but follows at least 
two different patterns. In one of them, mtDNA amount 
remains low throughout all age groups, while in the other it 
is already higher among young individuals and grows even 
more during aging. These patterns of variation of mtDNA 
with aging were named Mitochondriogenesis Pattern A 
(MP-A) and B (MP-B) respectively.
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Figure 1. Correlation of mtDNA copy number and age calculated with Pearson test for specimens with more (blue) and less (red) than 
1000 copies. Only the group with more than 1000 copies presented a significant correlation between mtDNA amount and age (p < 0,05)
In order to reach possible explanations for the 
different evolutions of mtDNA content with aging, the 
past medical history of the donors was evaluated. It was 
found that MP-B individuals had higher body mass index 
(BMI) than MP-A ones by Mann-Whitney test (p = 0.0280). 
Similar result was described in a study with omental adipose 
tissue, in which mtDNA amount was higher in obeses, that 
in non-obeses.4 It was also found that MP-B individuals 
diagnosed with diabetes mellitus had higher expression of 
PGC-1α, TFAM, TFB1M and TFB2M than non-diabetics 
by Mann-Whitney test (p = 0.0003; 0.0008; 0.0005 and 
0.0044 respectively). In MP-A group, no difference was 
observed between diabetics and non-diabetics. Of note, 
a previous study with peripheral blood cells found that 
diabetics have higher amount of mtDNA and mutations in 
the D-loop than non-diabetics5. D-loop is the region of the 
mtDNA where the promoters recognized by TFB1M and 
TFB2M are located,6 therefore mutations in D-loop may 
lead to a decreased affinity for the transcription factors, 
possibly resulting in an overexpression of those factors to 
compensate the lack of affinity.
The results achieved in the study support the idea 
that the mitochondriogenesis is upregulated in individuals 
with metabolic comorbidities, suggesting that the MP-B 
is probably linked to an unhealthy brain aging. Given that 
metabolic syndrome has an important role as a risk factor 
for Alzheimer’s Disease (AD)7 and that oxidative stress and 
mitochondrial dysfunction are part of AD pathogenesis8, 
the mtDNA increase in brain tissue could be studied not 
only as a biomarker of mitochondrial dysfunction, as Malik 
and Czajka (2013) proposed3, but also as a risk factor 
for Alzheimer’s Disease. Further investigation is needed 
to establish a more consistent relationship between the 
increased amount of mtDNA in brain tissue and AD so 
that, in the future, the experimental finding of the present 
study can be translated in a diagnostic tool.
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